Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07210229 · ClinicalTrials.gov registry record · NA
The Effectiveness of a Proprietary Ashwagandha Extract on Menopausal Symptoms: A Three-Arm Randomized, Double-Blinded, Placebo Controlled Clinical Trial
A NA study, sponsored by Nutraceuticals Research Institute.
- Not yet
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT07210229: Clinical Trial NA study, sponsored by Nutraceuticals Research Institute.
NCT07210229 is a NA study that has not yet begun recruiting, run by Nutraceuticals Research Institute. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07210229, a NA study, has not yet begun recruiting, sponsored by Nutraceuticals Research Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of two proprietary ashwagandha extracts on symptoms of menopause and hormone levels, as compared to a placebo.
Primary Outcome
Nutraceuticals Research Institute's Menopause Symptom Scale is a validated self-report scale measuring symptoms across 6 domains. Scores range from 0-30, with higher scores indicating greater symptom severity.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT ashwagandha root
- DIETARY_SUPPLEMENT ashwagandha root and leaf
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2026-03-30 |
| Phase | NA |
What is known before NCT07210229 opens enrollment
NCT07210229 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07210229 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07210229 about?
NCT07210229 is a clinical study titled "The Effectiveness of a Proprietary Ashwagandha Extract on Menopausal Symptoms: A Three-Arm Randomized, Double-Blinded, Placebo Controlled Clinical Trial". The purpose of this study is to evaluate the efficacy of two proprietary ashwagandha extracts on symptoms of menopause and hormone levels, as compared to a placebo.
What is the current status of trial NCT07210229?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2025-10-01. Estimated completion is 2026-03-30.
What interventions are being tested in trial NCT07210229?
The interventions under investigation include: Placebo (OTHER), ashwagandha root (DIETARY_SUPPLEMENT), ashwagandha root and leaf (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07210229?
This trial is sponsored by Nutraceuticals Research Institute, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07210229's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI